within Pharmacolibrary.Drugs.ATC.V;

model V08CA03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 7.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00023,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00011999999999999999,
    k12             = 0.2,
    k21             = 0.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08CA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gadodiamide is a non-ionic, linear gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to enhance the visibility of internal structures. It is indicated primarily for cranial, spinal, and whole-body MRI for the detection of lesions with abnormal vascularity. Its use has declined in some regions due to concerns of nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, but it may still be used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model and parameters based on healthy adult individuals (n≈13-110), both sexes, after intravenous administration of 0.1 mmol/kg.</p><h4>References</h4><ol><li><p>Harpur, ES, et al., &amp; Nomura, H (1993). Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. <i>Investigative radiology</i> 28 Suppl 1 S28–S43. DOI:<a href=\"https://doi.org/10.1097/00004424-199303001-00004\">10.1097/00004424-199303001-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8486501/\">https://pubmed.ncbi.nlm.nih.gov/8486501</a></p></li><li><p>Joffe, P, et al., &amp; Meusel, M (1998). Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. <i>Academic radiology</i> 5(7) 491–502. DOI:<a href=\"https://doi.org/10.1016/s1076-6332(98)80191-8\">10.1016/s1076-6332(98)80191-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9653466/\">https://pubmed.ncbi.nlm.nih.gov/9653466</a></p></li><li><p>Gambino, JM, et al., &amp; Lee, AM (2018). Retention of gadolinium in the brains of healthy dogs after a single intravenous administration of gadodiamide. <i>American journal of veterinary research</i> 79(9) 949–960. DOI:<a href=\"https://doi.org/10.2460/ajvr.79.9.949\">10.2460/ajvr.79.9.949</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30153053/\">https://pubmed.ncbi.nlm.nih.gov/30153053</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08CA03;
